You are here

omidubicel

Gamida lays off 17%, ditches NK cell therapy work to keep blood cancer drug on track

Fierce Biotech

Mon, 03/27/23 - 09:55 am

natural killer cells

FDA pushes back Gamida Cell’s PDUFA date by three months

Endpoints

Sun, 11/27/22 - 07:12 pm

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers

Businesswire

Thu, 09/29/22 - 09:59 am

Novartis-backed Gamida hits goal in phase 3 cancer trial

Fierce Biotech

Tue, 05/12/20 - 12:04 pm

clinical trials